Potent and selective monoacyglycerol acyltransferase 2 (MOGAT2) inhibitor (IC50 = 20 - 40 nM). Displays >7000-fold selectivity for human MOGAT2 over human DGAT2. Modulates intestinal lipid absorption in mice. Decreases triglyceride, diacylglycerol and fatty acid synthesis in mouse model of fatty liver. Chronic treatment decreases hepatic triglyceride content and body weight, and improves glucose tolerance in diet-induced obese mice.

Okuma et al (2015) JTP-103237, a novel monoacylglycerol acyltransferase inhibitor, modulates fat absorption and prevents diet-induced obesity. Eur.J.Pharmacol. 758 72 PMID:25857225 |Okuma et al (2015) JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis. J.Pharmacol.Sci. 128 150 PMID:26215699